The combination of dasatinib and quercetin—known as D+Q—has 1 in a human pilot study, providing the first clinical evidence that senolytic drugs can improve function in people with age-related disease.
The study, conducted at Mayo Clinic and 1 in eBioMedicine, tested the combination in patients with idiopathic pulmonary fibrosis—a fatal lung disease associated with senescent cell accumulation.
The Senolytic Hypothesis
Senescent cells accumulate with age and in disease states. While they stop dividing, they remain metabolically active, secreting inflammatory factors that damage surrounding tissue through the SASP. Senolytics selectively eliminate these cells—and in animal studies, clearing senescent cells extends healthspan and even lifespan. The D+Q combination was identified through systematic screening as an effective senolytic cocktail.
Why This Combination?
Dasatinib is an FDA-approved leukemia drug that inhibits multiple kinases that senescent cells rely on for survival. Quercetin is a natural flavonoid found in many fruits and vegetables that inhibits BCL-2 family anti-apoptotic proteins. Together, they target complementary survival pathways, making it harder for senescent cells to escape death.
Study Design and Results
The open-label pilot study enrolled 14 patients with idiopathic pulmonary fibrosis. Participants received D+Q orally for three consecutive days per week for three weeks. Physical function improved significantly: 6-minute walk distance increased by an average of 21.5 meters, gait speed improved, and patients showed improved ability to rise from a chair without arm support. Researchers also observed reduced circulating SASP factors in blood, and the treatment was well-tolerated with only mild side effects.
Limitations and Next Steps
This was a small, open-label study without a placebo control, so results must be interpreted cautiously. However, the biomarker changes and consistency across multiple physical measures are encouraging. Mayo Clinic is now conducting larger, randomized, placebo-controlled trials to confirm these findings.
Broader Implications
Dr. James Kirkland, the Mayo Clinic researcher who pioneered senolytics, emphasizes this is just the beginning: "We now have proof-of-concept that senolytics can benefit humans. The next generation of more targeted senolytics should be even more effective with fewer side effects."
Some longevity enthusiasts have begun self-experimenting with D+Q, but experts caution against this—dasatinib has significant side effects including bleeding risk and heart problems. Until proper dosing and safety protocols are established through clinical trials, self-administration carries real risks.
